# US 2020/0390733 A1 · Therapy for Transthyretin-Associated Amyloidosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390733 A1
- Document ID: US20200390733A1
- Status: Published application
- Kind: A1
- Application number: 17/005,893
- Filed: 2020-08-28
- Published: 2020-12-17
- Earliest claimed: 2011-10-24
- Assignees: SOM Innovation Biotech, S.L.
- Applicants: Som Innovation Biotech, S.L.
- Inventors: Marc Centellas Casado; Raúl Insa Boronat; Nuria Reig Bolaño; Núria Gavaldà Batalla
- Web page: https://patentgrep.com/patent/US20200390733A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/12: Ketones
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/603: having further aromatic rings, e.g. diflunisal
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

## Claims

### Claim 1

A catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis.

### Claim 2 (depends on 1)

The catechol-O-methyltransferase (COMT) inhibitor for use according to claim 1, wherein said COMT inhibitor is a nitrocatechol compound of formula I or a pharmaceutically acceptable salt thereof;
wherein R═—C(O)-PhCH3, —CH═C(N)—C(O)—NEt2 or —CH═C(O)(CH3)—C(O)(CH3).

### Claim 3 (depends on 2)

The catechol-O-methyltransferase (COMT) inhibitor for use according to claim 2, wherein the COMT inhibitor is tolcapone or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2, 3)

The catechol-O-methyltransferase (COMT) inhibitor for use according to any of the claims 1-3, wherein the transthyretin-associated amyloidosis is familial amyloid polyneuropathy.

### Claim 5 (depends on 1, 2, 3)

The catechol-O-methyltransferase (COMT) inhibitor for use according to any of the claims 1-3, wherein the transthyretin-associated amyloidosis is senile systemic amyloidosis.

### Claim 6 (depends on 1, 2, 3)

The catechol-O-methyltransferase (COMT) inhibitor for use according to any of the claims 1-3, wherein the transthyretin-associated amyloidosis is leptomeningeal amyloidosis.

### Claim 7 (depends on 1, 2, 3)

The catechol-O-methyltransferase (COMT) inhibitor for use according to any of the claims 1-3, wherein the transthyretin-associated amyloidosis is familial amyloid cardiomyopathy.

### Claim 8

A catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with an additional therapeutic agent selected from the group consisting of another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline and epigallocatechin-3-gallate, wherein the benzoxazole derivative is a compound of formula V
or a pharmaceutically acceptable salt thereof, wherein:
Y is COOR, tetrazolyl, CONHOR, B(OH)2 or OR;
X is 0; and
R1, R2 and R3 are each independently selected from hydrogen, halo, OR, B(OH)2 or CF3, and wherein
R is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 cycloalkyl, C1-C6 heterocyclyl, phenyl, xylyl, naphthyl, thienyl, indolyl or pyridyl.

### Claim 9 (depends on 8)

The catechol-O-methyltransferase (COMT) inhibitor for use according to claim 8, wherein the benzoxazole derivative is a compound of formula VI
or a pharmaceutically acceptable salt thereof, wherein:
Y is COOH, or OH; and
R1, R2 and R3 are each independently selected from hydrogen, halo, OH, B(OH)2 or CF3.

### Claim 10 (depends on 8, 9)

The catechol-O-methyltransferase (COMT) inhibitor for use according to any one of the claims 8-9, wherein the benzoxazole derivative is tafamidis.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The catechol-O-methyltransferase (COMT) inhibitor for use according to any of the claims 1-10, wherein the COMT inhibitor is administered as an injectable dosage form, as an oral dosage form or as a controlled release dosage form.

### Claim 12

A combination of a catechol-O-methyltransferase (COMT) inhibitor and an additional therapeutic agent selected from the group consisting of another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline and epigallocatechin-3-gallate, for use in the prevention and/or treatment of transthyretin-associated amyloidosis, wherein the benzoxazole derivative is a compound of formula V
or a pharmaceutically acceptable salt thereof, wherein:
Y is COOR, tetrazolyl, CONHOR, B(OH)2 or OR;
X is 0; and
R1, R2 and R3 are each independently selected from hydrogen, halo, OR, B(OH)2 or CF3, and wherein
R is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 cycloalkyl, C1-C6 heterocyclyl, phenyl, xylyl, naphthyl, thienyl, indolyl or pyridyl.

### Claim 13

A therapeutic agent selected from the group consisting of a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline and epigallocatechin-3-gallate, for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with a catechol-O-methyltransferase (COMT) inhibitor, wherein the benzoxazole derivative is a compound of formula V
or a pharmaceutically acceptable salt thereof, wherein:
Y is COOR, tetrazolyl, CONHOR, B(OH)2 or OR;
X is 0; and
R1, R2 and R3 are each independently selected from hydrogen, halo, OR, B(OH)2 or CF3, and wherein
R is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 cycloalkyl, C1-C6 heterocyclyl, phenyl, xylyl, naphthyl, thienyl, indolyl or pyridyl.
